Kokuma unveils new efficacy data for its depigmenting active ingredient
The Belgian biotechnology start-up Kokuma presented new findings on its patented depigmenting compound Tonasulike-D during the IFSCC 2025 Congress and the Cosmetic 360 event. First previewed in 2024, the ingredient is designed to safely and visibly reduce hyperpigmentation and enhance skin radiance across all examined skin types.
Dual mechanism and scientific approach
Tonasulike-D, discovered through AI-driven research, acts through a dual synergistic mechanism: it decreases melanin synthesis and blocks melanin transfer. Clinical trials indicate that even at a minimal concentration of 0.01%, the ingredient delivers measurable efficacy.
“By leveraging AI and biotechnology, we uncovered a potent new ingredient that delivers clinical results safely, setting new standards for depigmenting and brightening ingredients,” said Yannick Quesnel, Ph.D., Chief Scientific Officer and Co-founder of Kokuma.
Research results
In both in vitro and ex vivo studies, Tonasulike-D demonstrated clear improvement in skin tone and reduction of dark spots, confirming its effectiveness even at very low doses.
Author’s summary: Kokuma’s AI-developed Tonasulike-D shows strong depigmenting effects and enhanced skin radiance in clinical tests at only 0.01% concentration.